Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation

A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer

(2009) George Fountzilas et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase II study of sunitinib malate in head and neck squamous cell carcinoma

(2009) Nicholas W. Choong et al.   INVESTIGATIONAL NEW DRUGS

Gastrosplenic Fistula From Hodgkin's Lymphoma

(2009) Carolyn D. Seib et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Sunitinib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: GORTEC 2006-01

(2009) Jean-Pascal H. Machiels et al.   JOURNAL OF CLINICAL ONCOLOGY

Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials

(2009) Youjin Je et al.   LANCET ONCOLOGY

Hemostatic complications of angiogenesis inhibitors in cancer patients

(2008) Francesca Elice et al.   AMERICAN JOURNAL OF HEMATOLOGY

Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer

(2008) A A M van der Veldt et al.   BRITISH JOURNAL OF CANCER

Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: Current and future directions

(2008) Brigette B. Y. Ma et al.   CANCER SCIENCE

Severe Epistaxis with Tyrosine Kinase Inhibitors

(2008) P.S. Hall et al.   CLINICAL ONCOLOGY

Bowel Perforation After Radiotherapy in a Patient Receiving Sorafenib

(2008) Natascha A.J.B. Peters et al.   JOURNAL OF CLINICAL ONCOLOGY

High Frequency of Intracerebral Hemorrhage in Metastatic Renal Carcinoma Patients with Brain Metastases Treated with Tyrosine Kinase Inhibitors Targeting the Vascular Endothelial Growth Factor Receptor

(2007) Damien Pouessel et al.   EUROPEAN UROLOGY